297 related articles for article (PubMed ID: 37743048)
1. A multidisciplinary approach with immunotherapies for advanced hepatocellular carcinoma.
Lee YR
J Liver Cancer; 2023 Sep; 23(2):316-329. PubMed ID: 37743048
[TBL] [Abstract][Full Text] [Related]
2. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
3. Combination immunotherapy for hepatocellular carcinoma.
Rimassa L; Finn RS; Sangro B
J Hepatol; 2023 Aug; 79(2):506-515. PubMed ID: 36933770
[TBL] [Abstract][Full Text] [Related]
4. Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma.
Chen Y; Hu H; Yuan X; Fan X; Zhang C
Front Immunol; 2022; 13():896752. PubMed ID: 35757756
[TBL] [Abstract][Full Text] [Related]
5. The evolution of immune checkpoint inhibitor combinations in advanced hepatocellular carcinoma - A systematic review.
Meyers BM; Knox JJ; Liu DM; McLeod D; Ramjeesingh R; Tam VC; Lim HJ
Cancer Treat Rev; 2023 Jul; 118():102584. PubMed ID: 37336142
[TBL] [Abstract][Full Text] [Related]
6. The Treatment Landscape of Advanced Hepatocellular Carcinoma.
Wong KM; King GG; Harris WP
Curr Oncol Rep; 2022 Jul; 24(7):917-927. PubMed ID: 35347594
[TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies.
Ouyang T; Kan X; Zheng C
Front Oncol; 2022; 12():898964. PubMed ID: 35785169
[TBL] [Abstract][Full Text] [Related]
8. Tremelimumab: A Review in Advanced or Unresectable Hepatocellular Carcinoma.
France NL; Blair HA
Target Oncol; 2024 Jan; 19(1):115-123. PubMed ID: 38236364
[TBL] [Abstract][Full Text] [Related]
9. The emerging therapies are reshaping the first-line treatment for advanced hepatocellular carcinoma: a systematic review and network meta-analysis.
Peng W; Pan Y; Xie L; Yang Z; Ye Z; Chen J; Wang J; Hu D; Xu L; Zhou Z; Chen M; Fang A; Zhang Y
Therap Adv Gastroenterol; 2024; 17():17562848241237631. PubMed ID: 38645513
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular Carcinoma: Beyond the Border of Advanced Stage Therapy.
Zarlashat Y; Abbas S; Ghaffar A
Cancers (Basel); 2024 May; 16(11):. PubMed ID: 38893154
[TBL] [Abstract][Full Text] [Related]
11. Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma.
Carloni R; Sabbioni S; Rizzo A; Ricci AD; Palloni A; Petrarota C; Cusmai A; Tavolari S; Gadaleta-Caldarola G; Brandi G
J Hepatocell Carcinoma; 2023; 10():1445-1463. PubMed ID: 37701562
[TBL] [Abstract][Full Text] [Related]
12. Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma: A Review.
Cappuyns S; Corbett V; Yarchoan M; Finn RS; Llovet JM
JAMA Oncol; 2024 Mar; 10(3):395-404. PubMed ID: 37535375
[TBL] [Abstract][Full Text] [Related]
13. Advances in novel systemic therapies for advanced hepatocellular carcinoma.
Carloni R; Rizzo A; Cusmai A; Palloni A; Federico AD; Marco MD; Massafra R; Fanizzi A; Palmiotti G; Brandi G
Future Med Chem; 2022 Oct; 14(20):1455-1470. PubMed ID: 35997677
[TBL] [Abstract][Full Text] [Related]
14. The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma.
Lee MMP; Chan LL; Chan SL
J Liver Cancer; 2023 Sep; 23(2):262-271. PubMed ID: 37589044
[TBL] [Abstract][Full Text] [Related]
15. Updates on Systemic Therapy for Hepatocellular Carcinoma.
Ntellas P; Chau I
Am Soc Clin Oncol Educ Book; 2024 Jan; 44():e430028. PubMed ID: 38175973
[TBL] [Abstract][Full Text] [Related]
16. Impact and Novel Perspective of Immune Checkpoint Inhibitors in Patients with Early and Intermediate Stage HCC.
Marzi L; Mega A; Gitto S; Pelizzaro F; Seeber A; Spizzo G
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884392
[TBL] [Abstract][Full Text] [Related]
17. Balancing Efficacy and Tolerability of First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis.
Celsa C; Cabibbo G; Pinato DJ; Di Maria G; Enea M; Vaccaro M; Battaglia S; Rizzo GEM; Giuffrida P; Giacchetto CM; Rancatore G; Grassini MV; Cammà C
Liver Cancer; 2024 Apr; 13(2):169-180. PubMed ID: 38751554
[TBL] [Abstract][Full Text] [Related]
18. Locoregional Combined With Systemic Therapies for Advanced Hepatocellular Carcinoma: An Inevitable Trend of Rapid Development.
Li X; Wang Y; Ye X; Liang P
Front Mol Biosci; 2021; 8():635243. PubMed ID: 33928118
[TBL] [Abstract][Full Text] [Related]
19. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
20. Evolving Treatment of Advanced Hepatocellular Carcinoma in the Asia-Pacific Region: A Review and Multidisciplinary Expert Opinion.
Ogasawara S; Choo SP; Li JT; Yoo C; Wang B; Lee D; Chow PKH
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34071818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
